Go Therapeutics Overview
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Go Therapeutics General Information
Description
Developer of antibodies designed to fight against a novel class of tumor-specific glycoprotein antigens. The company's antibodies target O-linked glycoproteins specific to cancer cells to develop proprietary antibodies for a broad array of potent cancer-killing modalities including T-cell bispecifics (TCBs), CAR-T, and antibody-drug conjugates (ADCs), enabling patients to receive treatment for cancer without destroying any healthy tissue.
Contact Information
Website
www.gotherapeutics.comCorporate Office
- 22 Strathmore Road
- Natick, MA 01760
- United States
Corporate Office
- 22 Strathmore Road
- Natick, MA 01760
- United States
Go Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 3. Early Stage VC (Series A) | 08-Aug-2017 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | $2.5M | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 10-Aug-2009 | $2.5M | $2.5M | Completed | Generating Revenue |
Go Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A |
Go Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Go Therapeutics Patents
Go Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022339819-A1 | Anti-glyco-lamp1 antibodies and their uses | Pending | 03-Sep-2021 | ||
| AU-2022339667-A1 | Anti-glyco-cmet antibodies and their uses | Pending | 03-Sep-2021 | ||
| EP-4395810-A1 | Anti-glyco-cmet antibodies and their uses | Pending | 03-Sep-2021 | ||
| EP-4396232-A1 | Anti-glyco-lamp1 antibodies and their uses | Pending | 03-Sep-2021 | ||
| CA-3230934-A1 | Anti-glyco-cmet antibodies and their uses | Pending | 03-Sep-2021 | A61K40/11 |
Go Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Go Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ABI LAB | Accelerator/Incubator |
Go Therapeutics FAQs
-
Where is Go Therapeutics headquartered?
Go Therapeutics is headquartered in Natick, MA.
-
What is the size of Go Therapeutics?
Go Therapeutics has 9 total employees.
-
What industry is Go Therapeutics in?
Go Therapeutics’s primary industry is Drug Discovery.
-
Is Go Therapeutics a private or public company?
Go Therapeutics is a Private company.
-
What is Go Therapeutics’s current revenue?
The current revenue for Go Therapeutics is .
-
How much funding has Go Therapeutics raised over time?
Go Therapeutics has raised $7.5M.
-
Who are Go Therapeutics’s investors?
ABI LAB has invested in Go Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
